Citation Impact
Citing Papers
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations
2004
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
2005 StandoutNobel
Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism
2024 StandoutNobel
Cardiopulmonary function in two human disorders of the hypoxia‐inducible factor (HIF) pathway: von Hippel‐Lindau disease and HIF‐2α gain‐of‐function mutation
2011 StandoutNobel
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Comparative Sequence Analysis of the VHL Tumor Suppressor Gene
2000
Germline mutation profile of theVHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma
1998
Analysis of von Hippel—Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
2002
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
1999
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
2002
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
1997 StandoutNobel
The pressure rises: update on the genetics of phaeochromocytoma
2002
Von Hippel‐Lindau gene alterations in sporadic benign and malignant pheochromocytomas
2003
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis
1996
Elite and stochastic models for induced pluripotent stem cell generation
2009 StandoutNatureNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
Renal-Cell Carcinoma
1996 Standout
Renal Tumors in the Birt-Hogg-Dubé Syndrome
2002
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
2000
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
2001
Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein
2002
von Hippel-Lindau Disease
1997 StandoutNobel
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
1995 Science
Germline and Somatic Mutations in von Hippel-Lindau Disease Gene and Its Significance in the Development of Kidney Cancer
1999
Trichloroethylene Exposure and Specific Somatic Mutations in Patients With Renal Cell Carcinoma
1999
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
KLF4, p21 and context-dependent opposing forces in cancer
2005
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma
2001 StandoutNobel
A clinical and molecular genetic analysis of solitary ocular angioma
1999
von Hippel-Lindau disease
2003 Standout
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
1997
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
2001
Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene
1996
Cancer-epigenetics comes of age
1999 Standout
Germline mutations in thevhl gene in patients presenting with phaeochromocytomas
1998
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
2002
General Transcription Factors for RNA Polymerase II1
1997
VHL, the story of a tumour suppressor gene
2014
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL
1997
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
1998
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressor
2002
Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma
2002
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity
2003
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
2003
Differences in Allelic Distribution of Two Polymorphisms in the VHL-Associated GeneCUL2in Pheochromocytoma Patients without SomaticCUL2Mutations1
1999
Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas1
2000
Molecular genetic analysis of the von Hippel-Lindau disease (VHl) tumour suppressor gene in gonadal tumours
1995
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
1996
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
1999
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
2000 StandoutNobel
MUTATION OF THEVHL GENE IS ASSOCIATED EXCLUSIVELY WITH THE DEVELOPMENT OF NON-PAPILLARY RENAL CELL CARCINOMAS
1996
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
2002
Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ
1998
Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system
2001
HIF activation identifies early lesions in VHL kidneys
2002 StandoutNobel
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
2003
Software and database for the analysis of mutations in the VHL gene
1998
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
1999
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
1995
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
1996
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
2000
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
1995 StandoutScienceNobel
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL −/− clear cell renal carcinoma
2017 StandoutNobel
von Hippel-Lindau Disease
2006 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
1995
Structural Basis of Transcription: An RNA Polymerase II Elongation Complex at 3.3 Å Resolution
2001 StandoutScienceNobel
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
2000
The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
1996
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
1995
MUTATION OF THE VON HIPPEL-LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM
1996
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
1998 Standout
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.
1996
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss
2010 StandoutScienceNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function
1998
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
1996
Genotype–phenotype correlations in von hippel–lindau disease
1998
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
1998
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
2001
Genomic organization and chromosomal localization of the humanCUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development
1999
Haemangioblastoma of the central nervous system in von Hippel–Lindau disease
1998
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
2002
Architecture of RNA Polymerase II and Implications for the Transcription Mechanism
2000 StandoutScienceNobel
The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity
1997
Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
2002
Biallelic inactivation of hMLH 1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
1998 StandoutNobel
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
2001
Structural Basis of Transcription: RNA Polymerase II at 2.8 Ångstrom Resolution
2001 StandoutScienceNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
BIALLELIC INACTIVATION OF THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE IN SPORADIC RENAL CELL CARCINOMA
2002
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of Amanda Prowse being referenced
Somatic mutations of the von Hippel — Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma
1994
Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesis
1998
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
1997
Identification of intragenic mutations in the Von Hippel — Lindau disease tumour suppressor gene andcorrelation with disease phenotype
1994
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
1995